Document:

EX-10.22

 Exhibit 10.22 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE
INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

SUPPLY AGREEMENT 
 This
Supply Agreement (the “Agreement”) is made and entered into as of March 10, 2019 (the “Effective Date”) by and between EirGenix, Inc., a Taiwanese corporation having its principal place of business at
No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei City 22180, Taiwan (“EirGenix”), and Bolt Biotherapeutics, Inc., a Delaware corporation having its principal place of business at 640 Galveston Drive, Redwood City,
CA 94063 USA (“Bolt”). 
 RECITALS 

WHEREAS, EirGenix is engaged in the development and commercialization of biosimilar products as well as the provision of process development,
manufacturing and supply of monoclonal antibody products, including a biosimilar trastuzumab antibody designated internally by EirGenix as [***] (the “Antibody”); 

WHEREAS, Bolt is engaged in the research, development and commercialization of novel biotherapeutics that utilize tumor-targeting antibodies,
including biosimilar trastuzumab, 
 in combination with proprietary compositions and methods to improve overall therapeutic performance;
and WHEREAS, the Parties desire for EirGenix to supply the Antibody to Bolt subject to the terms and conditions set forth below. 
 NOW,
THEREFORE, in consideration of the premises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 - DEFINITIONS 

Whenever used in this Agreement, the following capitalized terms shall have the respective meanings as set forth below: 

1.1 “Adverse Event” means an adverse event associated with the use of the Antibody in humans that is reportable to Regulatory
Authorities in accordance with Applicable Laws in the Territory. 
 1.2 “Affiliate” means any corporation or other legal
entity controlling, controlled by or under common control with a Party. As used in this definition, “control” means the direct or indirect ownership of fifty percent (50%) or more of the voting securities of such corporation or other legal
entity or the power to direct the management of such corporation or other legal entity. 
 1.3 “Applicable Laws” means all
laws, ordinances, rules and regulations of any Regulatory Authority or other governmental authority that apply to the Antibody or this Agreement, including without limitation (a) all applicable federal, state and local laws and regulations;
(b) the U.S. Federal Food, Drug and Cosmetic Act; (c) International Conference on Harmonisation guidelines (ICH Q7); and (d) if applicable, cGMP and related standards promulgated by the FDA and other Regulatory Authorities. 

  
 - 1 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 1.4 “Boltbody” means a pharmaceutical preparation that is comprised of an
antibody in combination (through conjugation and/or co-formulation) with Bolt Technology that is designed to generate an immune response to cells targeted by an antibody. 

1.5 “Bolt Technology” means all compositions, methods and processes owned or otherwise controlled by Bolt that are designed
to stimulate an immune response to cells targeted by an antibody, and all intellectual property rights therein. 
 1.6 “Cell
Line” means the cGMP cell line used by EirGenix to express the Antibody. 
 1.7 “cGMP” means current good
manufacturing practices and standards as promulgated by the applicable Regulatory Authority in the United States and the European Union and the International Conference on Harmonization, as amended from time to time. 

1.8 “Drug Master File” means a submission to a Regulatory Authority of information concerning the chemistry, manufacturing
and controls of the Antibody to permit such Regulatory Authority to review such information in support of any application for Regulatory Approval. 

1.9 “EirGenix Technology” means compositions, methods and processes, and all supporting documentation, and other information
owned or otherwise controlled by EirGenix during the term of this Agreement relating to the Antibody, and all intellectual property rights in the foregoing. EirGenix Technology includes biological materials (including the Cell Line, critical
reagents and ancillary materials), know-how (including process related information, batch records, standard operating procedures, Antibody characterization information, analytical methods and information and
stability data), chemistry, manufacturing and controls data and procedures for quality control and testing of the Antibody, and any patents and other intellectual property rights as may be necessary or useful for the development, manufacture or
commercialization of the Product. 
 1.10 “Party” means either EirGenix or Bolt and “Parties” means both EirGenix
and Bolt. 
 1.11 “Phase I Clinical Trial” means a human clinical study of a Product, the principal purpose of which is a
preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a) (as amended or any replacement thereof), or a similar human clinical study prescribed by the Regulatory Authority in a country other than the
United States. 
 1.12 “Phase III Clinical Trial” means a human clinical study of a Product, the design of which is
acknowledged by the FDA to be sufficient for such clinical study to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical study prescribed by the Regulatory Authority in a country other
than the United States. Phase III Clinical Trial also includes (a) the portion of any human clinical study that meets the foregoing definition, as in the case of a study designated as a “Phase II/III” clinical trial, and (b)

  
 - 2 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
any other human clinical study serving as a pivotal study from which the data are actually submitted to the applicable Regulatory Authority in connection with an application for Regulatory
Approval, whether or not such study is expressly designated as a “Phase III” clinical trial. 
 1.13
“Product” means a Boltbody comprising the Antibody. 
 1.14 “Regulatory Approval” means, with respect to a
product, all approvals, licenses, registrations or authorizations necessary to market and sell such product in a particular jurisdiction in the Territory (including applicable approvals of labeling, price and reimbursement for such product in such
jurisdiction). 
 1.15 “Regulatory Authority” means any governmental authority involved in regulating any aspect of the
manufacture, sale, distribution, or use of the Antibody or the Product, as applicable, including the United States Food and Drug Administration (“FDA”). 

1.16 “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence,
registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority (including minutes of meeting with Regulatory Authorities) that are necessary or reasonably desirable to access in
connection with the development, manufacture, marketing, sale or other commercialization of any pharmaceutical product in a particular country or regulatory jurisdiction. Regulatory Materials include Investigational New Drug Applications and
Biologics License Applications (each as defined under FDA regulations), clinical trial applications, marketing approval applications and applications for pricing approvals. 

1.17 “Related Product” means any product comprising a Boltbody immune stimulator conjugated or
co-formulated with the Antibody. 
 1.18 “Specifications” means the written
specifications for the Antibody as defined and set forth in Exhibit A hereto and which may be changed from time to time in accordance with Section 2.3. 

1.19 “Territory” means worldwide. 

1.20 Additional Definitions. Each of the following terms shall have the meaning described in the corresponding Section of this
Agreement indicated below: 
  

			
	Term	  	Section
	Agreement	  	First Paragraph
	Antibody	  	Recitals
	Antibody Warranty	  	9.2(a)
	Bolt	  	First Paragraph
	Change of Control	  	13.6
	CMO	  	4.4(b)
	Commercial Supply Price	  	8.1
	Confidential Information	  	11.1

  
 - 3 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

			
	Data Package	  	7.3
	Direct Manufacturing Cost	  	8.1
	Disclosing Party	  	11.1
	Effective Date	  	First Paragraph
	EirGenix	  	First Paragraph
	Failure to Supply	  	4.4(a)
	FCPA	  	9.2(e)
	FDA	  	1.15
	Forecast	  	3.1
	Indemnitee	  	10.3
	Indemnitor	  	10.3
	Initial Development Quantity	  	5.1
	Inspection Period	  	6.1
	Prior Agreements	  	11.1
	Prior MTA	  	13.7
	Quality Agreement	  	2.5
	Receiving Party	  	11.1
	Recipients	  	11.2
	Supply Price	  	5.1

 ARTICLE 2 - SUPPLY 

2.1 In General. EirGenix shall supply Bolt with Antibody under the terms and conditions contained in this Agreement. 

2.2 Permitted Use. Bolt shall use the Antibody solely for the purpose of researching, developing, manufacturing and commercializing the
Product. For the avoidance of doubt, Bolt shall not commercialize the Antibody as a standalone biosimilar product. 
 2.3 Changes in
Manufacture. EirGenix will provide Bolt with at least [***] prior written notice of any proposed changes in the Specifications (as defined in Schedule A), and neither EirGenix nor any of its contract manufacturers shall implement any such change
without Bolt’s prior written approval, except to the extent such change is required by written directive of the FDA, the European Medicines Agency, Japan’s Pharmaceuticals and Medical Devices Agency or Taiwan’s Food and Drug
Administration. Any such permitted changes to the Specifications of the Antibody shall be signed by an authorized representative of each of the Parties, and shall be effective for purchase orders of the Antibody placed after the effective date of
such changes. 
 2.4 EirGenix Technology. Except as expressly stated in this Agreement, each Party retains all right, title and
interest in and to any intellectual property owned or developed by such Party. Nothing in this Agreement is to be construed as granting a license to a Party to utilize the Confidential Information or intellectual property of the other Party except
as expressly provided in this Agreement. Bolt will not seek to commercialize trastuzumab supplied by EirGenix as a biosimilar or on a stand-alone basis or any form of derivative (other than a Boltbody) and will use such Antibody solely for the
research, development and commercialization of Boltbodies. 

  
 - 4 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 2.5 Quality Agreement. Within ninety (90) calendar days following the Effective
Date, the Parties shall enter into a mutually agreeable quality agreement, in accordance with Bolt’s and EirGenix’s standard operating procedures and in conformity with Applicable Laws (the “Quality Agreement”). To the
extent that any inconsistencies or conflicts exist between the Quality Agreement and this Agreement, the provisions in this Agreement shall prevail, except with respect to quality assurance matters related to the Antibody, in which case the Quality
Agreement shall prevail. 
 2.6 Quality Assurance. Subject to the terms and conditions of the Quality Agreement, EirGenix shall
maintain ongoing written quality assurance and testing procedures in compliance with Applicable Laws and this Agreement. During the term of this Agreement, EirGenix shall ensure that the manufacturing facilities for the Antibody are in compliance
with Applicable Laws and maintain such registrations, licenses and permits as may be necessary to supply Antibody to Bolt hereunder for incorporation into a Product. 

2.7 Quality Control. EirGenix shall ensure the manufacture of the Antibody in compliance with the Antibody Warranty. Prior to each
shipment of Antibody, EirGenix shall perform quality control procedures reasonably necessary to ensure that the Antibody to be shipped complies fully with the Antibody Warranty. Each shipment of Antibody shall be accompanied by a certificate of
analysis and a certificate of compliance describing all current requirements of the applicable Specifications and results of tests performed certifying that the quantities of Antibody supplied have been manufactured, controlled and released at the
applicable manufacturing facility according to the Specifications and Applicable Laws in a format (and based upon such analytical methods) as mutually agreed by the Parties. EirGenix will retain samples of each batch of the Antibody it manufactures,
and produce and maintain batch records with respect to each batch, in each case as required by Applicable Laws, and upon request, will provide such samples and copies of such batch records to Bolt. 

2.8 Deviations. Without limiting EirGenix’s obligations under Section 2.7 above, in the event any deviation from the
Specifications occurs during the course of manufacturing any batch of Antibody under this Agreement, EirGenix shall promptly provide Bolt with a detailed written description of such deviation and, to the extent known by EirGenix, an explanation of
the cause of such deviation. In addition to the provision of such notice, EirGenix shall undertake those actions to investigate the cause of such deviation and to correct the same as set out in this Agreement and the Quality Agreement, and as
otherwise reasonably requested by Bolt. 
 2.9 Inspections. EirGenix shall, upon reasonable notice, permit authorized representatives
of Bolt, [***] and during normal working hours, to enter and inspect the facilities where the Antibody is manufactured, tested or stored (including related batch records and other manufacturing records), for purposes of verifying that such
facilities and operations comply with the terms and conditions of this Agreement and with Applicable Laws. Bolt shall also have the right to observe the manufacture of the Antibody, upon reasonable notice, at any time when the Antibody is being
manufactured, and to inspect and audit records and data relating to the manufacture, testing and storage of the Antibody. 

  
 - 5 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 2.10 Additional Studies. Upon request by Bolt, EirGenix may perform specific
additional scopes of work (e.g. container compatibility, sample testing, and/or stability studies) in accordance with regulatory filing requirements, in each case based upon a scope of work mutually agreed upon by the Parties in writing and at
EirGenix’s standard rates for similar services. 
 2.11 Recalls of Product. Bolt shall have the sole right to initiate any
recall of a Product. EirGenix shall provide assistance and cooperation to Bolt (or its designee), as reasonably requested, in conducting any such recall, including assisting and cooperating with investigations and providing all pertinent records
that may assist Bolt in effecting such recall. If such recall arises out of or results from (i) the negligence or willful misconduct of EirGenix or (ii) a breach of this Agreement by EirGenix (including a breach of any of the
representations or warranties in Article 9), EirGenix shall bear the portion of the costs and expenses of such recall corresponding to EirGenix’s responsibility. 

2.12 Exclusivity. EirGenix shall not, directly or indirectly (through any other person, entity or otherwise), develop, manufacture,
sell, market, promote or distribute any Related Product in the Territory, nor sell or otherwise transfer the Antibody to any third party for the development, manufacture, sale, marketing, promotion or distribution of any Related Product in the
Territory. 
 2.13 Subcontractors. EirGenix may not subcontract all or any part of its obligations under this Agreement to any third
party unless: (i) Bolt provides its prior written consent, (ii) the subcontractor is bound in writing to perform the subcontracted services in accordance with this Agreement and (iii) EirGenix remains fully responsible to Bolt for the
performance of such services by the subcontractor (including any breach of this Agreement by the subcontractor). Except for the subcontractors which EirGenix has already used for certain bioanalytical tests, viral clearance study, bulk harvest viral
tests, leachable & extractable tests, and cell bank characterizations. 
 2.14 Executive Meetings. The [***] of EirGenix and
the [***] of Bolt shall meet [***] to discuss the Parties’ cooperation at a mutually acceptable time and location. 
 ARTICLE 3 -
FORECASTS AND ORDERS 
 3.1 Forecasts. Commencing upon commercialization of the Product, at least [***] prior to the end of
each [***], Bolt will provide EirGenix with an estimate of Bolt’s anticipated orders of the Antibody for the following [***] on a [***] basis (each, a “Forecast”). The final [***] of each Forecast are non-binding and provided for planning purposes only. The initial [***] of each Forecast are binding to the extent provided in the table below and Bolt will submit firm purchase orders for such binding quantities in
accordance with Section 3.2. Prior to commercialization of the Product (i.e., for purposes of pre-clinical and clinical development of the Product), Bolt estimates that it shall order approximately [***]
of the Antibody for delivery in the [***] and shall provide additional estimates, from time to time, through meetings of the Parties’ respective project managers, all such estimates being non-binding and
provided for planning purposes only. 
  

					
	 Months
	  	Binding Percentage of
Commercial Forecast	 
		
	 [***]
	  	 	[	***] 

  
 - 6 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 3.2 Purchase Orders. Bolt shall submit to EirGenix its firm purchase orders for the
Antibody, specifying: (i) the quantity of the Antibody ordered, (ii) the requested delivery date in accordance with the applicable lead time as set forth in the table below and (iii) whether such order has a significant time deadline.

  

					
	 Quantity
	  	Lead Time to Delivery	 
		
	 [***]
	  	 	[	***] 

 3.3 Acceptance of Purchase Orders. All purchase orders for the Antibody submitted by Bolt in accordance
with this Article 3 shall be deemed accepted by EirGenix upon receipt. Within [***] following receipt of a purchase order, EirGenix will confirm in writing the delivery date for the Antibody. 

ARTICLE 4 - DELIVERY 

4.1 Delivery. The Antibody ordered by Bolt hereunder shall be delivered [***], via a carrier reasonably acceptable to Bolt, at which
time title and risk of loss shall transfer to Bolt. Bolt shall be responsible for all shipping costs invoiced by EirGenix as set forth in Section 5.2. Each shipment of the Antibody shall be accompanied by a certificate of analysis and
certificate of compliance as set forth in Section 2.7. If requested by Bolt, each shipment will contain satellite samples for testing. 

4.2 Responsibility for Export/Import Licenses. EirGenix shall procure all necessary licenses or permits required to supply and export
the Antibody, and Bolt shall procure any necessary licenses or permits required to receive and import the Antibody. The Parties will reasonably cooperate with each other to effect compliance with all applicable export and import laws and regulations
applicable to their activities under this Agreement. 
 4.3 Delays. If EirGenix fails to deliver any Antibody by the applicable
delivery date confirmed as set forth in Section 3.3 without prior consent by Bolt, and such delay in delivery is not caused by circumstances outside of EirGenix’s control, EirGenix will [***]. For the avoidance of doubt, such [***] is not
applicable to delays caused by force majeure events or custom delay provided EirGenix fulfills its obligations with respect to such force majeure events as set forth in Section 13.2. 

4.4 Failure to Supply. 

(a) During the term of this Agreement, EirGenix shall continue to manufacture the Antibody at its facilities located in [***]. In the event
EirGenix foresees or becomes aware that it will be unable to deliver any shipment of the Antibody in the quantity and by the delivery date specified by Bolt in a purchase order (each a “Failure to Supply”), EirGenix shall promptly
notify Bolt in writing. In such event, the Parties shall promptly convene to identify the actions necessary 

  
 - 7 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
to address the problem. EirGenix shall use its best efforts to promptly remedy any Failure to Supply and resume supplying Antibody meeting the requirements of this Agreement to Bolt as soon as
possible. All costs and expenses required to remedy a Failure to Supply and incurred by EirGenix shall be borne by EirGenix. 
 (b) In the
event of a Failure to Supply, EirGenix shall quickly select and establish an alternative manufacturer (which alternative manufacturer shall be reasonably acceptable to Bolt) (a “CMO”) to continue manufacturing the Antibody. EirGenix
will be responsible for technology transfer costs associated with the establishment of such alternative manufacturer. The technology transfer and establishing an alternative manufacturer will be performed diligently by EirGenix but may take [***],
and [***]. EirGenix will use its best efforts to continue to supply quantities of [***] to minimize the impact on Bolt’s clinical development and/or commercialization until sufficient supply is available to meet Bolt’s needs. Bolt shall
also have the right to terminate this Agreement in its entirety immediately upon written notice to EirGenix in the event a Failure to Supply continues for more than [***]. In addition, Bolt shall have the right to cancel orders for any quantities of
Antibody affected by such Failure to Supply effective upon notice to EirGenix, and Bolt shall have no further obligations to purchase any such cancelled quantities of Antibody. 

(c) In the event of Failure to Supply, and EirGenix does not obtain the regulatory approval from FDA for the Antibody as a standalone
biosimilar product, plus if EirGenix could not establish an alternative manufacturer as set forth in Section 4.4(b), both Parties will [***], to the extent necessary or useful for Bolt to manufacture or have manufactured a sufficient supply of
Antibody, [***]. 
 ARTICLE 5 - PRICE AND PAYMENT 

5.1 Supply Price. The supply price of the Antibody under this Agreement for use in pre-clinical
and clinical development activities (the “Supply Price”) is [***] as of the Effective Date, and is subject to adjustment [***] in proportion to [***]. For clarity, the Parties agree and acknowledge that Bolt already received [***]
of the Antibody in drug substance form in [***] (the “Initial Development Quantity”). 
 5.2
Invoicing & Cancellation. Excluding shipments of the Initial Development Quantity, for which EirGenix may invoice Bolt in full after the Effective Date for any amounts outstanding, EirGenix shall issue invoices to Bolt
for (i) [***] of the purchase price upon [***] and (ii) [***] of the purchase price upon Bolt’s completion of acceptance testing pursuant to Section 6.1. Invoices shall include shipping costs actually incurred by EirGenix for delivery of
the Antibody. Bolt shall pay each undisputed invoice within [***] after the date of receipt of such invoice. Interest shall accrue on late payments at [***]. 

Prior to commencing upon commercialization of the Products, any cancellation [***]. If the cancellation occurred [***] for the order prior to
the scheduled production date, Bolt shall [***]. After the commercialization, it will set forth as “Forecast” defined in 3.1, any binding orders shall be paid in full. 

  
 - 8 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 5.3 Use and Fees for Using [***]’s Regulatory Data Package. Subject to delivery
of the Data Package and continued supply by EirGenix of Antibody ordered by Bolt in accordance with Article 3, Bolt shall pay the amounts set forth below within [***] after the earliest date on which the corresponding milestone event has first been
achieved by or on behalf of Bolt: 
 [***] 

Each milestone payment in this Section 5.3 shall be payable only once; no amounts shall be due for subsequent or repeated achievements of
such milestone with respect to the same or another Product. 
 5.4 Payment. All payments to be made by Bolt to EirGenix under this
Agreement shall be made by wire transfer to the following bank account (or other account designated by EirGenix from time to time) in U.S. Dollars without deducting any charge for remittance: 

BANK ACCOUNT 
 Bank Name:
[***] 
 Bank Address: [***] 

Account Name: [***] 
 Bank Swift
Code: [***] 
 Account Number: [***] 

5.5 Taxes. EirGenix agrees that the Supply Price shall be inclusive of, and that EirGenix shall bear, all local (Taiwan, ROC) taxes,
whether direct or indirect (including, by way of example, corporate income, sales and transfer taxes, and VAT), local levies and duties (including customs duties) as may be imposed on EirGenix (or for which EirGenix is required to act as withholding
agent by the local governmental authority), and EirGenix shall be responsible for the timely payment of such amounts to the local governmental authority. 

5.6 Recordkeeping. During the term of this Agreement EirGenix shall prepare and retain, and shall cause its contractors (including any
CMO) to prepare and retain, accurate books and records related to transactions made pursuant to this Agreement, subject to such record retention and destruction provisions as set forth in the Quality Agreement and as may otherwise be required by
Applicable Laws. Such records shall be made available for reasonable review, audit and inspection upon reasonable notice and with reasonable frequency, upon Bolt’s request for the purpose of verifying EirGenix’s calculations of amounts due
hereunder, and the basis for such calculations or payments. Audits and inspections may be conducted by Bolt’s own personnel or retained consultant(s), subject to the confidentiality obligations set forth in this Agreement. 

ARTICLE 6 - ACCEPTANCE 

6.1 Inspection. Bolt and its contractors shall inspect the Antibody promptly after receipt of any shipment with sufficient time to
complete all acceptance testing and inspections (the “Inspection Period”) to check whether the Antibody conforms to the Antibody Warranty. It is estimated that the Inspection Period shall take approximately [***]. 

  
 - 9 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 6.2 Claim and Remedy for Non-conformity. If
Bolt determines that any shipment of the Antibody does not conform to the Antibody Warranty, Bolt shall inform EirGenix in writing of such non-conformity, including a description of the non-conformity, within the Inspection Period. If Bolt informs EirGenix of such non-conformity, upon EirGenix’s request, Bolt shall provide EirGenix with a reasonable
sample of such Antibody in question for EirGenix’s testing. Bolt shall deliver the sample to EirGenix in accordance with such transportation instructions as provided by EirGenix. If EirGenix’s testing confirms such non-conformity, then such replacement shall be at EirGenix’s sole cost and expense (including the cost for the transportation of the sample to EirGenix). If EirGenix’s testing indicates that such Antibody
conforms to the Antibody Warranty, EirGenix and Bolt shall cooperate to determine whether or not the Antibody conforms to the Antibody Warranty, and if the Parties cannot reach an agreement, Bolt shall submit a sample of the Antibody to an
independent laboratory reasonably acceptable to EirGenix and Bolt for further testing. The results of the testing by such independent laboratory shall be binding on both Parties. If it is shown by the independent laboratory that the Antibody
conforms to the Antibody Warranty, Bolt shall bear the cost for the replacement Antibody, the testing by the independent laboratory and the transportation of the samples to EirGenix. If it is shown by the independent laboratory that the Antibody
fails to conform to the Antibody Warranty, EirGenix shall bear the cost for the replacement Antibody, the testing by the independent laboratory and the transportation of the sample to EirGenix. The rejected shipment of the Antibody will then, at
EirGenix’s sole discretion, be destroyed or returned to EirGenix at EirGenix’s cost and expense. Except in the case of a latent defect (as noted in the following sentence), the obligations of EirGenix under this Section 6.2 shall not
arise unless a written notice of an alleged non-conformity by Bolt is made to EirGenix within the Inspection Period. Notwithstanding the foregoing, Bolt shall have the right to reject any shipment of the
Antibody that fails to conform to the Antibody Warranty, if such non-conformity was not reasonably susceptible to discovery based upon Bolt’s acceptance testing and inspection and Bolt provides notice to
EirGenix within [***] after its discovery thereof; provided that such non-conformity is not directly attributable to Bolt’s or its agents’ handling, distribution or storage of the Antibody. 

ARTICLE 7 - REGULATORY MATTERS 

7.1 Regulatory Actions. EirGenix shall permit Regulatory Authorities to conduct such inspections of the manufacturing facilities of
EirGenix or its third party contractors at which any of the manufacturing activities relating to the Antibody are performed and of relevant records related thereto, as such Regulatory Authorities may request, including
pre-approval inspections, and shall cooperate with such Regulatory Authorities with respect to such inspections and any related matters, in each case that is related to the manufacture and supply of the
Antibody. If the inspection is related to Bolt Products, Bolt shall bear all the related inspection cost. EirGenix shall give Bolt prompt written notice of any such inspections relating to the Related Product, and shall keep Bolt informed about the
results and conclusions of each such regulatory inspection, including actions taken by EirGenix to remedy conditions cited in such inspections. In addition, EirGenix shall allow Bolt or its representative to assist in the preparation for and be
present at such inspections. EirGenix shall [***] provide Bolt with copies of 483 warning letters or equivalent form by any Regulatory Authority and all correspondence between EirGenix and any Regulatory Authority with respect thereto, in each case
relating to the Antibody, its manufacture or general 

  
 - 10 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
manufacturing concerns (e.g., facility compliance or the like). Additionally, EirGenix agrees to notify and provide Bolt copies of any request. Prior to responding to such 483 warning letters or
equivalent form issued by any Regulatory Authority relating to the Antibody or its manufacture or general manufacturing issues, EirGenix shall provide to Bolt a copy of its proposed response within sufficient time for Bolt to review prior to
submitting such response to the applicable Regulatory Authority. 
 7.2 Regulatory Cooperation. EirGenix agrees to cooperate fully
and promptly provide to Bolt, as reasonably requested by and at no charge to Bolt, reasonable information and data in EirGenix’s possession or control necessary or useful for Bolt or its designee(s) to apply for, obtain and maintain Regulatory
Approvals for the Product in the Territory, or otherwise required or requested to be provided to any Regulatory Authority in connection with the Product. In addition, EirGenix agrees to reasonably cooperate with Bolt or its designees with respect to
obligations to submit or report information relevant to the Product to Regulatory Authorities pursuant to Applicable Laws. 
 7.3 Data
Package; Drug Master Files; Right of Reference. Within [***] following the Effective Date, EirGenix shall provide Bolt with a chemistry, manufacturing, controls document set forth on Exhibit B (collectively, the “Data Package”).
Bolt shall pay EirGenix for time spent by personnel of EirGenix in providing the initial Data Package to Bolt at an hourly rate of [***], to be invoiced by EirGenix upon delivery of such Data Package. In addition, EirGenix hereby grants to Bolt and
its designees the right to use EirGenix Technology, including the data and information contained in the Data Package for purposes of developing, obtaining Regulatory Approvals for and commercializing the Product in the Territory, and to incorporate
such data and information into Regulatory Materials. EirGenix hereby grants to Bolt and its designees the right to reference its Regulatory Materials, including any Drug Master File, for purposes of obtaining Regulatory Approvals for the Product in
the Territory, and upon request EirGenix shall promptly execute and deliver such additional documents and instruments, and provide such additional authorizations, to the applicable Regulatory Authorities as appropriate to effect such right of
reference. EirGenix shall be responsible, at EirGenix’s expense, for maintaining any such Drug Master File and promptly correcting any deficiencies therein that are identified by the applicable Regulatory Authority, in accordance with
Applicable Laws. 
 7.4 Safety Data. EirGenix shall promptly inform Bolt in writing of any information regarding Adverse Events or
other safety issues related to the use of the Antibody of which it becomes aware in a timely manner commensurate with the seriousness of the event to allow Bolt to comply with Applicable Laws. 

7.5 Cooperation. Each Party agrees to (i) make its personnel reasonably available at their respective places of employment to
consult with the other Party on issues related to the activities conducted in accordance with this Article 7 or otherwise relating to the development of the Antibody or the Product and thereafter in connection with any request from any Regulatory
Authority, including with respect to regulatory, scientific, technical and clinical testing issues, and (ii) otherwise provide such assistance as may be reasonably requested by the other Party from time to time in connection with the activities
to be conducted under this Article 7, or otherwise relating to the development of the Antibody or the Product. 

  
 - 11 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 ARTICLE 8 - COMMERCIAL SUPPLY 

8.1 The Parties agree that, at least [***] prior to the [***], they will negotiate in good faith and enter into an amendment to this Agreement
setting forth the terms and conditions for long term commercial supply of the Antibody (in drug substance form) compliant with cGMP. The Parties agree and acknowledge that the supply price per gram for such commercial stage supply of the Antibody
(the “Commercial Supply Price”) will be the [***]. “[***]” means [***]. Alternatively, if mutually agreed by the Parties, EirGenix shall supply Bolt with the Antibody (in drug substance form) for commercialization
at a mutually agreed Commercial Supply Price [***]. For reference purposes only, the 2018 supply price of the Antibody (in drug substance form) is [***], and if such supply price becomes fixed based upon a specified price agreed at a specific time,
such price shall be subject to adjustment [***] in proportion to [***]. In addition, this Agreement, as so amended with respect to commercial supply, shall contain provisions with respect to the continuity of supply no less favorable to Bolt than as
set forth in Section 4.4. The above pricing for [***] is based on [***]. If [***], the price would be [***]. 
 ARTICLE 9 -
REPRESENTATIONS AND WARRANTIES 
 9.1 Mutual Representations and Warranties. Each Party represents and warrants to the other
Party that: (i) it is duly incorporated and validly existing under the laws of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; (ii) it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; (iii) this Agreement
is legally binding upon it and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party
or by which it may be bound, nor violate any Applicable Laws; (iv) it has not granted, and will not grant during the term of this Agreement, any right to any third party which would conflict with the rights granted to the other Party hereunder;
and (v) it is not aware of any action, suit, inquiry or investigation instituted by any third party which questions or threatens the validity of this Agreement. 

9.2 Additional Representations and Warranties. EirGenix further represents and warrants to Bolt that: 

(a) the Antibody supplied to Bolt hereunder shall: (i) conform to the Specifications (as defined in Schedule A) and comply with all
Applicable Laws, including cGMP, and EirGenix shall perform and document all manufacturing and supply activities contemplated herein in compliance with all Applicable Laws; (ii) have not less than [***] of shelf life remaining at the time of
receipt by Bolt, unless otherwise agreed upon by Bolt; and (iii) be free and clear of any security interest, lien or other encumbrance (collectively (clauses (i), (ii) and (iii)), the “Antibody Warranty”); 

  
 - 12 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 (b) the manufacturing facilities, the equipment used in the manufacture of Antibody within
such facilities and the activities contemplated herein shall comply with all Applicable Laws, and EirGenix shall obtain (prior to performing the relevant obligations), and maintain during the term of this Agreement, all governmental registrations,
permits, licenses and approvals necessary for EirGenix to manufacture and supply the Antibody to Bolt, and otherwise to perform its obligations, under this Agreement; 

(c) neither EirGenix, nor any of its Affiliates, nor any of their respective employees performing or involved with the performance under this
Agreement, has been “debarred” by a Regulatory Authority in any jurisdiction, nor have debarment proceedings against EirGenix, any of its Affiliates, or any of their respective employees been commenced. EirGenix will promptly notify Bolt
in writing if any such proceedings have commenced or if EirGenix, any of its Affiliates, or any of their respective employees are debarred by a Regulatory Authority in any jurisdiction; 

(d) EirGenix owns or possesses adequate licenses and other rights to any intellectual property to be used by EirGenix in fulfilling its
obligations under this Agreement, and its manufacture and supply of the Antibody and fulfillment of its obligations under this Agreement shall not infringe, misappropriate or violate the intellectual property rights of any third party; and 

(e) in the performance of its obligations under this Agreement, EirGenix will not act in any fashion or take any action which will render Bolt
liable for a violation of the U.S. Foreign Corrupt Practices Act (“FCPA”), which prohibits the offering, giving or promising to offer or give, directly or indirectly, money or anything of value to any official of a government,
political party or instrumentality thereof in order to assist EirGenix or Bolt in obtaining or retaining business. Bolt shall have the right to immediately terminate this Agreement should EirGenix make any payment, or take any other action, which
would violate the FCPA. 
 ARTICLE 10 - INDEMNIFICATION; LIABILITY 

10.1 Indemnification by Bolt. Bolt shall indemnify, defend and hold harmless EirGenix, its Affiliates and their respective directors,
officers, employees and agents from and against any and all liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) arising or resulting from any claims made or suits brought by a third party which
arise or result from: [***], except in each case with respect to any matter for which EirGenix is obligated to provide indemnification under Section 10.2. 

10.2 Indemnification by EirGenix. EirGenix shall indemnify, defend and hold harmless Bolt, its Affiliates and their respective
directors, officers, employees and agents from and against any and all liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) arising or resulting from any claims made or suits brought by a third
party which arise or result from: [***], except in each case to with respect to any matter for which Bolt is obligated to provide indemnification under Section 10.1. 

10.3 Indemnification Procedure. A Party that intends to claim indemnification, on behalf of itself or any of its Affiliates, or any of
their respective directors, officers, employees or agents 

  
 - 13 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
(each, an “Indemnitee”), under this Article 10 shall promptly notify the other Party (the “Indemnitor”) in writing of the applicable claim, provided, however,
that the failure to give such notice shall not limit or otherwise reduce the indemnity provided for in this Agreement except to the extent that failure to give notice materially prejudices the rights of the Indemnitor. The Indemnitor shall have the
right, upon notice to the Indemnitee within [***] after the receipt of any such notice, to undertake the defense, settlement or compromise of such claim, and the failure of the Indemnitor to give such notice and to undertake the defense of or to
settle or compromise such a claim shall constitute a waiver of the Indemnitor’s rights under this Section 10.3 and shall preclude the Indemnitor from disputing the manner in which the Indemnitee may conduct the defense of such claim. Upon
such notice from the Indemnitor, the Indemnitor shall have sole control of the defense and/or settlement of such claim; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the
defense and/or settlement of such claim. The Indemnitor shall not settle any claim without the prior written consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed. The indemnification obligations of the Parties under
this Article 10 shall not apply to amounts paid in settlement of any claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed. The Indemnitee, and its employees, at the
Indemnitor’s request and expense, shall provide full information and reasonable assistance to the Indemnitor and its legal representatives with respect to such claims covered by this indemnification. 

10.4 Limitation on Liability. Except with respect to any breach of Article 11, [***] or a Party’s indemnification obligations
under this Article 10, neither Party shall be liable to the other Party for lost profits, lost savings or any indirect, punitive, exemplary, incidental, consequential or special damages of whatever nature, even if such Party has knowledge of the
possibility of such potential loss or damages. 
 10.5 Insurance. Each Party shall maintain at its sole cost and expense adequate
liability insurance (including product liability insurance) with reputable and financially secure insurance carriers to protect against potential liabilities and risks arising out of activities to be performed under this Agreement and upon such
terms (including coverages and deductible limits) as are customary in the pharmaceutical industry for the activities to be conducted by such Party under this Agreement. The coverage limits set forth in any such insurance policy shall not create any
limitation on a Party’s liability to the other Party under this Agreement. Each Party shall furnish to the other Party upon request certificates issued by the applicable insurance company(ies) setting forth the amount of such liability
insurance. 
 ARTICLE 11 - CONFIDENTIALITY 

11.1 Definition. “Confidential Information” means all information and data that is disclosed or provided by or on
behalf of a Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) or to any of the Receiving Party’s Affiliates or representatives in connection with this Agreement (including the
information of a third party), including such information or data disclosed or provided prior to the Effective Date. This Article 11 shall supersede that certain Confidentiality Agreement between the Parties dated August 1, 2017 and that
certain Mutual 

  
 - 14 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
Confidentiality Agreement among EirGenix, Bolt and Piramal Enterprises Limited dated June 20, 2018 (collectively, the “Prior Agreements”), and all Confidential Information
as defined and disclosed between the Parties pursuant to the Prior Agreements shall be deemed to have been disclosed hereunder. 
 11.2
Obligations. The Receiving Party shall protect all Confidential Information of the Disclosing Party against unauthorized use and disclosure to third parties with the same degree of care as the Receiving Party uses for its own information of a
similar nature, and in no event less than a reasonable degree of care. The Receiving Party shall be permitted to use the Confidential Information of the Disclosing Party solely as reasonably necessary to exercise its rights and fulfill its
obligations under this Agreement (including any surviving rights), including (a) in prosecuting or defending litigation, (b) complying with Applicable Laws, or (c) otherwise submitting information to Regulatory Authorities or other
governmental authorities. The Receiving Party shall not disclose the Confidential Information of the Disclosing Party to any third party other than to its Affiliates and their respective directors, officers, employees, contractors, licensees and
professional advisors (collectively, “Recipients”) who have a need to know such information for purposes related to this Agreement, or the development, manufacture or commercialization of the applicable Product, are made aware of
the non-disclosure and non-use obligations set forth in this Agreement and are bound by obligations of non-disclosure and non-use consistent with this Agreement. The Receiving Party shall be responsible for any disclosures or use of Confidential Information by its Recipients in violation of this Agreement. 

11.3 Exceptions. Confidential Information shall not include any information to the extent the Receiving Party can demonstrate by
competent evidence that such information: 
 (a) is or becomes known to the public or part of the public domain through no wrongful act or
omission by the Receiving Party (including the Receiving Party’s Recipients); 
 (b) was known to, or was otherwise in the possession
of, the Receiving Party prior to the time of disclosure by the Disclosing Party; 
 (c) is disclosed to the Receiving Party on a non-confidential basis by a third party who is not, to the actual knowledge of the Receiving Party, breaching any confidentiality obligation to the Disclosing Party by disclosing such information; or 

(d) is independently developed by or on behalf of the Receiving Party or any of its Affiliates without use of or reference to the Confidential
Information of the Disclosing Party. 
 11.4 Disclosure Required by Law. The restrictions set forth in this Article 11 shall not
apply to the extent that the Receiving Party is required to disclose any Confidential Information of the Disclosing Party under law or by an order of a Regulatory Authority; provided that the Receiving Party: (a) provides the Disclosing Party
with prompt written notice of such disclosure requirement if legally permitted, (b) cooperates with the Disclosing Party’s efforts to oppose or limit, or secure confidential treatment for, such required disclosure at the Disclosing
Party’s expense, and (c) if the Disclosing Party is unsuccessful in its efforts pursuant to subsection (b), discloses only that portion of the Confidential Information that the Receiving Party is legally

  
 - 15 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
required to disclose as advised by the Receiving Party’s legal counsel. Any Confidential Information so disclosed shall maintain its confidentiality protection for all purposes other than
such legally compelled disclosure. 
 11.5 Nondisclosure of Agreement. Each Party agrees not disclose the terms and conditions of
this Agreement to any third party without the prior written consent of the other Party, which consent shall not be unreasonably withheld, except to such Party’s professional advisors, existing and potential investors, licensees, collaborators
and acquirers and others on a reasonable need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, and provided that Bolt may inform its
customers, suppliers and business contacts that EirGenix supplies the Antibody to Bolt. Notwithstanding the foregoing, each Party may make announcements concerning the subject matter of this Agreement to the extent required by Applicable Laws or any
securities exchange, Regulatory Authority or tax authority. 
 11.6 Right to Injunctive Relief. Each Party agrees that breaches of
this Article 11 may cause irreparable harm to the other Party and shall entitle such other Party, in addition to any other remedies available to it, to the right to seek injunctive relief enjoining such action. 

11.7 Ongoing Obligation for Confidentiality. The Parties’ obligations of non-disclosure
and non-use under this Article 11 shall survive any expiration or termination of this Agreement for [***]. 

ARTICLE 12 - TERM AND TERMINATION 

12.1 Term. This Agreement shall become effective as of the Effective Date and shall remain in effect during the period in which Bolt or
any of its Affiliates or licensees continues to pursue the development or commercialization of any Product. 
 12.2 Termination. This
Agreement may be terminated by mutual written agreement of both Parties at any time, by Bolt pursuant to Section 4.4, by Bolt upon at least sixty (60) days prior written notice or by either Party upon written notice to the other Party if:

 (a) the other Party becomes subject to any voluntary or involuntary bankruptcy proceeding that is not dismissed within sixty
(60) days; or 
 (b) the other Party commits a material breach of this Agreement and such other Party does not remedy the default
within sixty (60) days of receiving a written demand to do so; provided, however, that if the Party alleged to be in breach of this Agreement disputes such breach within such sixty (60) day period, the
non-breaching Party shall not have the right to terminate this Agreement unless it has been determined pursuant to Section 13.4 that this Agreement was materially breached, and the breaching Party fails
to cure the breach within sixty (60) days after such determination. 
 (c) Bolt has the right to terminate this Agreement if EirGenix
does not obtain the regulatory approval from FDA for the Antibody as a standalone biosimilar product. 

  
 - 16 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 (d) EirGenix has the right to terminate this Agreement if Bolt has not been able to actively
develop the Product for more than 2 years. 
 12.3 Effect of Termination. In the event of any termination of this Agreement pursuant
to Section 4.4 or 12.2, EirGenix shall continue to fulfill any purchase orders submitted within [***] after the effective date of termination; provided that, to the extent Bolt notifies EirGenix, Bolt shall have the right to cancel any
outstanding purchase orders and have no further obligation to purchase any Antibody ordered under such outstanding purchase orders. This Section 12.3 sets forth Bolt’s sole and exclusive obligations and liability to EirGenix with respect
to purchases of the Antibody upon termination of this Agreement. 
 12.4 Survival. Sections 2.11, 5.3, 5.5, 5.6, 6.2, 12.3 and 12.4
and Articles 1, 9, 10, 11 and 13 shall survive the termination or expiration of this Agreement. All other rights and obligations of the Parties under this Agreement shall cease upon termination or expiration of this Agreement. It is understood that
termination or expiration of this Agreement shall not relieve a Party from any liability that, at the time of such termination or expiration, has already accrued to the other Party, except as specified in Section 12.3 above. 

ARTICLE 13 – MISCELLANEOUS 

13.1 Notice. Any notice or other communication required or permitted to be given under this Agreement shall be in English in writing,
addressed to the applicable Party at its respective address set forth below, or to such other address as such Party may designate in writing. Any such notice or other communication shall be deemed to have been duly given to the Party when delivered,
if delivered personally or sent by electronic transmission later confirmed in writing, or [***] after mailing, if sent by registered or certified mail, return receipt requested, postage prepaid, or by reputable international courier service. 

 

			
	 To EirGenix:
	  	 To Bolt:

	 EirGenix, Inc.
	  	 Bolt Biotherapeutics, Inc.

	 No. 101, Lane 169
	  	 640 Galveston Drive

	 Kangning Street, Xizhi District
	  	 Redwood City, CA 94063

	 New Taipei City 22180, Taiwan
	  	 USA

	 Attn: [***]
	  	 Attn: [***]

	Email: [***]	  	Email: [***]

 All financial invoices to Bolt shall be emailed to: [***]. 

13.2 Force Majeure. If the performance of this Agreement or any obligations hereunder is prevented, restricted or interfered with by
reason of earthquake, fire, flood or other casualty or due to strikes, riot, storms, explosions, acts of God, war, terrorism or a similar occurrence or condition beyond the reasonable control of the Parties, the Party so affected shall, upon giving
prompt written notice to the other Party, be excused from such performance during such prevention, restriction or interference, and any failure or delay resulting therefrom shall not be considered a breach of this Agreement, so long as the affected
Party takes commercially reasonable steps to relieve the effect of such cause as rapidly as reasonably possible. In addition, the Parties 

  
 - 17 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
shall discuss the effect of such event on this Agreement and the measures to be taken. For clarity, the Parties agree and acknowledge that this Section 13.2 shall not limit the rights of
Bolt in connection with a Failure to Supply under Section 4.4. 
 13.3 Governing Law. The validity, construction and performance
of this Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, U.S.A., without regard to any choice or conflict of laws rule or principle that will result in the application of the laws of any other
jurisdiction. 
 13.4 Dispute Resolution. Any dispute arising out of or relating to this Agreement, or the breach thereof, shall be
referred first to [***] and [***] for amicable resolution. If such dispute has not been resolved within [***], either Party may refer such dispute to binding arbitration conducted in [***] under the rules of the [***]. Further, each Party agrees
that any such arbitration shall be conducted in the English language and that process may be served upon them in any manner authorized by the laws of the State of [***] for such persons and waives and covenants not to assert or plead any objection
that it might otherwise have to such arbitral tribunal or such service of process. Each Party agrees not to commence any legal proceedings based upon or arising out of this Agreement in a court of law, except that a Party may seek a temporary
restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the selection of the arbitrator or pending the
arbitrator’s determination of the merits of any dispute pursuant to this Section 13.4. 
 13.5 Amendment. No amendment or
modification to this Agreement shall be effective and binding on either Party unless made in writing and executed by duly authorized representatives of the Parties. 

13.6 Assignment. This Agreement and any of the rights and obligations hereunder shall not be assigned by either Party without the prior
written consent of the other Party, which consent will not be unreasonably withheld; provided, however, that a Party may make such an assignment without the other Party’s consent to an Affiliate or to a third party successor to all or
substantially all of the business of such Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction (a “Change of Control”). In the event an assignment is consented to by the
other Party or is otherwise permitted hereunder, this Agreement shall inure to the benefit of and be binding upon the successor or the assignee. Any assignment not in accordance with this Section 13.6 shall be null and void. 

13.7 Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof
and supersedes all prior written or oral agreements and understandings between the Parties with respect thereto. This Agreement expressly supersedes the Material Transfer Agreement between the Parties dated August 24, 2017 (the “Prior
MTA”), as amended, and all materials and information provided by EirGenix under the Prior MTA shall be deemed Antibody and EirGenix’s Confidential Information, respectively, for purposes of this Agreement and shall be subject to the
terms of this Agreement. 
 13.8 Independent Contractors. EirGenix and Bolt are independent contractors. Nothing in this Agreement is
intended or shall be deemed to constitute a partnership, agency, employer-

  
 - 18 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 
employee, or joint venture relationship between the Parties and neither Party shall have any authority to enter into any contracts or assume any obligations on behalf of the other Party, nor
shall either Party represent itself as having such authority on behalf of the other Party. 
 13.9 No Waiver. No waiver of any breach
will constitute a waiver of any subsequent or continuing breach. The failure of either Party to assert any claim in a timely fashion will not alter or restrict any such Party’s right to assert any claim for a subsequent breach of this
Agreement. 
 13.10 Severability. If any provision of this Agreement is found to be invalid or unenforceable for any reason, the
remaining provisions shall be construed and applied so as to most closely effectuate its intent. The invalidity or non-enforceability of any provision of this Agreement in any jurisdiction shall not cause the
invalidity of the whole Agreement as to such jurisdiction, and shall not affect the validity or enforceability of such provision in any other jurisdiction. 

13.11 Headings; Interpretation. The headings contained in this Agreement are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word
“or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The term “including,” “include,” or “includes”
as used herein shall mean including without limiting the generality of any description preceding such term. 
 13.12 Exhibits. The
Exhibits listed below and attached hereto shall be deemed to form an integral part of this Agreement: 
 Exhibit A: Specifications 

Exhibit B: Data Package 
 13.13
English Language. All notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language. This Agreement was prepared in
the English language, and the English language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. 

(The remainder of this page is intentionally left blank. The signature page follows.) 

  
 - 19 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective
Date by their duly authorized representatives. 
  

									
	EirGenix, Inc.	 		 	Bolt Biotherapeutics, Inc.
			
	 /s/ Lee-Cheng
(L-C) Liu
	 		 	 /s/ Grant Yonehiro

	Name:	 	Lee-Cheng (L-C) Liu	 		 	Name:	 	Grant Yonehiro
	Title:	 		 		 	Title:	 	
					
	Date:	 	 2019/03/10
	 		 	Date:	 	 11 March 2019

  
 - 20 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 Exhibit A 

Specifications 
 [***]

  
 - 21 - 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE
BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. 

 

 Exhibit B 

Data Package 
 [***] 

  
 - 22 -EX-10.24

 Exhibit 10.24 

BOLT BIOTHERAPEUTICS, INC. 

SEVERANCE AND CHANGE IN CONTROL PLAN 

APPROVED BY THE BOARD OF DIRECTORS:
                    , 2021 

Section 1.    INTRODUCTION. 

The Bolt Biotherapeutics, Inc. Severance and Change in Control Plan (the “Plan”) is hereby established effective
upon the IPO Date (as defined below). The purpose of the Plan is to provide for the payment of severance and/or Change in Control (as defined below) benefits to eligible key employees of Bolt Biotherapeutics, Inc. (the
“Company”) in the event that such individuals become subject to certain involuntary or constructive employment terminations. Except as otherwise provided in an individual Participation Agreement, this Plan shall
supersede any severance or change in control benefit plan, policy or practice previously maintained by the Company, and any such benefits set forth in any individually negotiated employment letter or agreement between the Company and an individual
employee or other service provider. This Plan document also is the Summary Plan Description for the Plan. 
 For purposes of the Plan, the
following terms are defined as follows: 
 (a)    “Affiliate” means any corporation (other
than the Company) in an “unbroken chain of corporations” beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined
voting power of all classes of stock in one of the other corporations in such chain. 
 (b)    “Base
Salary” means base pay (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect prior to any reduction that would give rise to an employee’s right to resign for
Good Reason (if applicable). 
 (c)    “Board” means the Board of Directors of the
Company; provided, however, that if the Board has delegated authority to administer the Plan to the Compensation Committee of the Board, then “Board” shall also mean the Compensation Committee of the Board. 

(d)    “Cause” means, with respect to a particular employee, the meaning ascribed to such
term in any written agreement between such employee and the Company defining such term, and, in the absence of such agreement, means with respect to such employee, the term “Cause,” as defined in the Equity Plan. The determination whether
a termination is for Cause shall be made by the Plan Administrator in its sole and exclusive judgment and discretion. 

(e)    “Change in Control” has the meaning ascribed to such term in the Equity Plan. 

(f)    “Change in Control Period” means the period commencing three (3) months prior
to the effective date of a Change in Control and ending twelve (12) months following the effective date of such Change in Control. 

(g)    “Change in Control Termination” means an Involuntary Termination that occurs within
the Change in Control Period. For such purposes, if the events giving rise to an employee’s right to resign for Good Reason arise within the Change in Control Period, and the employee’s resignation occurs not later than thirty
(30) days after the expiration of the Cure Period (as defined below), such termination shall be a Change in Control Termination. 

  
 1. 

 (h)    “COBRA” means the Consolidated
Omnibus Budget Reconciliation Act of 1985. 
 (i)    “Code” means the Internal Revenue
Code of 1986, as amended, including any applicable regulations and guidance thereunder. 

(j)    “Company” means Bolt Biotherapeutics, Inc. or, following a Change in Control, the
surviving entity resulting from such event. 
 (k)    “Covered Termination” means a
Regular Termination or a Change in Control Termination. 
 (l)    “Director” means
a member of the Board. 
 (m)    “Disability” means any physical or mental condition
which renders an employee incapable of performing the work for which he or she was employed by the Company or similar work offered by the Company. The Disability of an employee shall be established if (i) the employee satisfies the
requirements for benefits under the Company’s long-term disability plan or (ii) if no long-term disability plan, the employee satisfies the requirements for Social Security disability benefits. 

(n)    “Eligible Employee” means an employee of the Company that meets the requirements to
be eligible to receive Plan benefits as set forth in Section 2 and is designated in writing as eligible to participate in the Plan by the Plan Administrator. 

(o)    “Entity” means a corporation, partnership, limited liability company
or other entity. 
 (p)    “Equity Plan” means the Bolt Biotherapeutics, Inc. 2021 Equity
Incentive Plan, as amended from time to time, or any successor plan thereto. 
 (q)    “Good
Reason” for an employee’s resignation has the meaning ascribed to such term in any written agreement between such employee and the Company defining such term, and, in the absence of such agreement, means with respect to such
employee the occurrence of any of the following events, conditions or actions taken by the Company without Cause and without such employee’s consent: (i) a material reduction of such employee’s annual base salary, which is a reduction
of at least 10% of such employee’s base salary (unless pursuant to a salary reduction program applicable generally to the Company’s similarly situated employees); (ii) a material reduction in such employee’s authority, duties or
responsibilities, provided, however, that a change in job position or level (including a change in title) shall not be deemed a “material reduction” in and of itself unless such employee’s new duties and responsibilities are
substantially reduced from the prior duties and responsibilities; (iii) a material breach by the Company of any provision of this Plan or any other material agreement between such employee and the Company concerning the terms and conditions of
such employee’s employment with the Company; or (iv) a relocation of such employee’s principal place of employment with the Company (or successor to the Company, if applicable) to a place that increases such employee’s one-way commute by more than fifty (50) miles as compared to such employee’s then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary course
of business); provided that, if such employee’s principal place of employment is his or her personal residence, this clause (iv) shall not apply; provided, however, that in each case above, in order for the employee’s
resignation to be deemed to have been for Good Reason, the employee must first give the Company written notice of the action or omission giving rise to “Good Reason” within thirty (30) days after the first occurrence thereof; the
Company must fail to reasonably cure such action or omission within thirty (30) days after receipt of such notice (the “Cure Period”), and the employee’s resignation must be effective not later than thirty (30) days
after the expiration of such Cure Period. 

  
 2. 

 (r)    “Involuntary Termination” means a
termination of employment that is due to: (1) a termination by the Company without Cause (and other than as a result of the employee’s death or Disability) or (2) an employee’s resignation for Good Reason, provided that in any
case such termination is also a Separation from Service. 
 (s)    “IPO Date” means the
date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the common stock, of the Company pursuant to which the common stock of the Company is priced for the initial public offering. 

(t)    “Own,” “Owned,” “Owner,”
“Ownership” means a person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or
indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(u)    “Participation Agreement” means an agreement between an employee and the Company in
substantially the form of Appendix A attached hereto, and which may include such other terms as the Board deems necessary or advisable in the administration of the Plan. 

(v)    “Plan Administrator” means the Board prior to the effective date of a Change in
Control and the Representative upon and following such date. 

(w)    “Representative” means one or more members of the Board or other
persons or entities designated by the Board prior to or in connection with a Change in Control that will have authority to administer and interpret the Plan upon and following the effective date of such Change in Control as provided in
Section 10(a). 
 (x)    “Regular Termination” means an Involuntary Termination that
is not a Change in Control Termination. 

(y)    “Section 409A” means Section 409A of the Code
and the treasury regulations and other guidance thereunder and any state law of similar effect. 

(z)    “Separation from Service” means a “separation from service” within the
meaning of Treasury Regulations Section 1.409A-1(h), without regard to any alternative definition thereunder. 

Section 2.    ELIGIBILITY FOR BENEFITS. 

(a)    Eligible Employee. An employee of the Company is eligible to participate in the Plan if (i) the
Board has designated such employee as eligible to participate in the Plan by providing such person with a Participation Agreement; (ii) such employee has signed and returned such Participation Agreement to the Company within the period
specified therein; (iii) such employee’s employment with the Company terminates due to a Covered Termination; and (iv) such employee meets the other Plan eligibility requirements set forth in this Section 2. The determination of
whether an employee is an Eligible Employee shall be made by the Plan Administrator, in its sole discretion, and such determination shall be binding and conclusive on all persons. 

  
 3. 

 (b)    Release Requirement. Except as otherwise provided
in an individual Participation Agreement, in order to be eligible to receive benefits under the Plan, the employee also must execute a general waiver and release, in such a form as provided by the Company (the “Release”),
within the applicable time period set forth therein, and such Release must become effective in accordance with its terms, which must occur in no event more than sixty (60) days following the date of the applicable Covered Termination. 

(c)    Exceptions to Benefit Entitlement. An employee who otherwise is an Eligible Employee will not receive
benefits under the Plan in the following circumstances, as determined by the Plan Administrator in its sole discretion: 

(1)    The employee is terminated by the Company for any reason or voluntarily terminates employment with the
Company in any manner (including due to the employee’s death or Disability), and in either case, such termination does not constitute a Covered Termination. Voluntary terminations include, but are not limited to, resignation, retirement or
failure to return from a leave of absence on the scheduled date. 
 (2)    The employee voluntarily terminates
employment with the Company in order to accept employment with another entity that is wholly or partly owned (directly or indirectly) by the Company or an Affiliate. 

(3)    The employee is offered an identical or substantially equivalent or comparable position with the Company or
an Affiliate. For purposes of the foregoing, a “substantially equivalent or comparable position” is one that provides the employee substantially the same level of responsibility and compensation and would not give rise to the
employee’s right to resign for Good Reason. 
 (4)    The employee is offered immediate reemployment by a
successor to the Company or an Affiliate or by a purchaser of the Company’s assets, as the case may be, following a Change in Control and the terms of such reemployment would not give rise to the employee’s right to resign for Good Reason.
For purposes of the foregoing, “immediate reemployment” means that the employee’s employment with the successor to the Company or an Affiliate or the purchaser of its assets, as the case may be, results in uninterrupted
employment such that the employee does not incur a lapse in pay or benefits as a result of the change in ownership of the Company or the sale of its assets. For the avoidance of doubt, an employee who becomes immediately reemployed as described in
this Section 2(c)(4) by a successor to the Company or an Affiliate or by a purchaser of the Company’s assets, as the case may be, following a Change in Control shall continue to be an Eligible Employee following the date of such
reemployment. 
 (d)    Termination of Severance Benefits. An Eligible Employee’s right to receive
severance benefits under this Plan shall terminate immediately if, at any time prior to or during the period for which the Eligible Employee is receiving severance benefits under the Plan, the Eligible Employee, without the prior written approval of
the Plan Administrator, engages in a Prohibited Action (as defined below). In addition, if benefits under the Plan have already been paid to the Eligible Employee and the Eligible Employee subsequently engages in a Prohibited Action during the
Prohibited Period (or it is determined that an Eligible Employee engaged in a Prohibited Action prior to receipt of such benefits), any benefits previously paid to the Eligible Employee shall be subject to recoupment by the Company on such terms and
conditions as shall be determined by the Plan Administrator, in its sole discretion. The “Prohibited Period” shall commence on the date of the Eligible Employee’s Covered Termination and continue for the number of months
corresponding to the Severance Period set forth in such Eligible Employee’s Participation Agreement. A “Prohibited Action” shall occur if the Eligible Employee: (i) 

  
 4. 

 
breaches any material statutory, common law, or contractual obligation to the Company or an Affiliate (including, without limitation, the contractual obligations set forth in the Company’s
standard employee confidentiality agreement, the Release and/or any other obligations of confidentiality, non-solicitation, non-disparagement, no conflicts or non-competition set forth in the Eligible Employee’s employment agreement, offer letter, any other written agreement between the Eligible Employee and the Company, or under applicable law); (ii) encourages or
solicits any of the Company’s then current employees to leave the Company’s employ for any reason or interferes in any other manner with employment relationships at the time existing between the Company and its then current employees; or
(iii) induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees, or other third parties to terminate their existing business relationship with the Company or interferes in any
other manner with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor, licensor, licensee, or other third parties. 

Section 3.    AMOUNT OF BENEFIT. 

(a)    Severance Benefit. Benefits under the Plan shall be provided to an Eligible Employee as set forth in
the Participation Agreement. 
 (b)    Additional Benefits. Notwithstanding the foregoing, the Company
may, in its sole discretion, provide benefits to employees or consultants who are not Eligible Employees (“Non-Eligible Employees”) chosen by the Board, in its sole discretion, and the
provision of any such benefits to a Non-Eligible Employee shall in no way obligate the Company to provide such benefits to any other Non-Eligible Employee, even if
similarly situated. If benefits under the Plan are provided to a Non-Eligible Employee, references in the Plan to “Eligible Employee” (and similar references) shall be deemed to refer to such Non-Eligible Employee. 
 (c)    Certain Reductions. The Company, in its
sole discretion, shall have the authority to reduce an Eligible Employee’s severance benefits, in whole or in part, by any other severance benefits, pay and benefits provided during a period following written notice of a plant closing or mass
layoff, pay and benefits in lieu of such notice, or other similar benefits payable to the Eligible Employee by the Company or an Affiliate that become payable in connection with the Eligible Employee’s termination of employment pursuant to
(i) any applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other similar state law, (ii) any individually negotiated employment contract or agreement or any other
written employment or severance agreement with the Company, or (iii) any Company policy or practice providing for the Eligible Employee to remain on the payroll for a limited period of time after being given notice of the termination of the
Eligible Employee’s employment, and the Plan Administrator shall so construe and implement the terms of the Plan. Any such reductions that the Company determines to make pursuant to this Section 3(c) shall be made such that any benefit
under the Plan shall be reduced solely by any similar type of benefit under such legal requirement, agreement, policy or practice (i.e., any cash severance benefits under the Plan shall be reduced solely by any cash payments or severance
benefits under such legal requirement, agreement, policy or practice, and any continued insurance benefits under the Plan shall be reduced solely by any continued insurance benefits under such legal requirement, agreement, policy or practice). The
Company’s decision to apply such reductions to the severance benefits of one Eligible Employee and the amount of such reductions shall in no way obligate the Company to apply the same reductions in the same amounts to the severance benefits of
any other Eligible Employee, even if similarly situated. In the Company’s sole discretion, such reductions may be applied on a retroactive basis, with severance benefits previously paid being
re-characterized as payments pursuant to the Company’s statutory obligation. 

  
 5. 

 (d)    Parachute Payments. Except as otherwise provided in
an individual Participation Agreement, if any payment or benefit an Eligible Employee will or may receive from the Company or otherwise (a “Payment”) would (i) constitute a “parachute payment” within the
meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such Payment shall be equal to the Reduced
Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to
and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all
computed at the highest applicable marginal rate), results in the Eligible Employee’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the
Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner
(the “Reduction Method”) that results in the greatest economic benefit for the Eligible Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata
(the “Pro Rata Reduction Method”). 
 Notwithstanding any provisions in this Section above to the contrary, if the
Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method
and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent
possible, the greatest economic benefit for the Eligible Employee as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being
terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall
be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A. 
 The Company shall
appoint a nationally recognized accounting or law firm to make the determinations required by this Section 3. The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.
If the Eligible Employee receives a Payment for which the Reduced Amount was determined pursuant to clause (x) above and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Eligible
Employee agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) above) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the
Reduced Amount was determined pursuant to clause (y) above, the Eligible Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. 

Section 4.    RETURN OF COMPANY PROPERTY. 

An Eligible Employee will not be entitled to any severance benefit under the Plan unless and until the Eligible Employee returns all Company
Property. For this purpose, “Company Property” means all Company documents (and all copies thereof) and other Company property which the Eligible Employee had in his or her possession at any time, including, but not limited
to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, research and development information, sales and marketing information, operational and personnel information,
specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones, servers), credit cards, entry cards, identification badges
and keys; and any materials of any kind which 

  
 6. 

 
contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). As a condition to receiving benefits under the Plan, an Eligible
Employee must not make or retain copies, reproductions or summaries of any such Company documents, materials or property. However, an Eligible Employee is not required to return his or her personal copies of documents evidencing the Eligible
Employee’s hire, termination, compensation, benefits and stock options and any other documentation received as a stockholder of the Company. 

Section 5.    TIME OF PAYMENT AND FORM
OF BENEFIT. 
 The Company reserves the right in the Participation Agreement to specify whether severance
payments under the Plan will be paid in a single sum, in installments, or in any other form and to determine the timing of such payments. All such payments under the Plan will be subject to applicable withholding for federal, state and local taxes.
If an Eligible Employee is indebted to the Company on his or her termination date, the Company reserves the right to offset any severance payments under the Plan by the amount of such indebtedness. All severance benefits provided under the Plan are
intended to satisfy the requirements for an exemption from application of Section 409A to the maximum extent that an exemption is available and any ambiguities herein shall be interpreted accordingly; provided, however, that to the extent such
an exemption is not available, the severance benefits provided under the Plan are intended to comply with the requirements of Section 409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be
interpreted accordingly. 
 Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under the Plan
that constitute “deferred compensation” within the meaning of Section 409A shall not commence in connection with an Eligible Employee’s termination of employment unless and until the Eligible Employee has also incurred a
“Separation from Service,”, unless the Company reasonably determines that such amounts may be provided to the Eligible Employee without causing the Eligible Employee to incur the adverse personal tax consequences under Section 409A.

 It is intended that (i) each installment of any benefits payable under the Plan to an Eligible Employee be regarded as a separate
“payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), (ii) all payments of any such benefits under the Plan satisfy, to the greatest extent possible, the exemptions from the
application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), and (iii) any such benefits consisting of
COBRA premiums also satisfy, to the greatest extent possible, the exemption from the application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(9)(v). However, if the Company
determines that any such benefits payable under the Plan constitute “deferred compensation” under Section 409A and the Eligible Employee is a “specified employee” of the Company, as such term is defined in
Section 409A(a)(2)(B)(i), then, solely to the extent necessary to avoid the imposition of the adverse personal tax consequences under Section 409A, (A) the timing of such benefit payments shall be delayed until the earlier of
(1) the date that is six (6) months and one (1) day after the Eligible Employee’s Separation from Service and (2) the date of the Eligible Employee’s death (such applicable date, the “Delayed Initial Payment
Date”), and (B) the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the benefit payments that the Eligible Employee would otherwise have received through the Delayed Initial Payment Date if
the commencement of the payment of the benefits had not been delayed pursuant to this paragraph and (2) commence paying the balance, if any, of the benefits in accordance with the applicable payment schedule. 

In no event shall payment of any benefits under the Plan be made prior to an Eligible Employee’s termination date or prior to the
effective date of the Release. If the Company determines that any payments or benefits provided under the Plan constitute “deferred compensation” under Section 409A, and the Eligible Employee’s Separation from Service occurs at a
time during the calendar year 

  
 7. 

 
when the Release could become effective in the calendar year following the calendar year in which the Eligible Employee’s Separation from Service occurs, then regardless of when the Release
is returned to the Company and becomes effective, the Release will not be deemed effective any earlier than the latest permitted effective date (the “Release Deadline”). If the Company determines that any payments or benefits
provided under the Plan constitute “deferred compensation” under Section 409A, then except to the extent that payments may be delayed until the Delayed Initial Payment Date pursuant to the preceding paragraph, on the first regular
payroll date following the effective date of an Eligible Employee’s Release, the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the benefit payments that the Eligible Employee would otherwise have
received through such payroll date but for the delay in payment related to the effectiveness of the Release and (2) commence paying the balance, if any, of the benefits in accordance with the applicable payment schedule. 

All severance payments under the Plan shall be subject to applicable withholding for federal, state and local taxes. If an Eligible Employee
is indebted to the Company at his or her termination date, the Company reserves the right to offset any severance payments under the Plan by the amount of such indebtedness.     

Section 6.    TRANSFER AND ASSIGNMENT. 

The rights and obligations of an Eligible Employee under this Plan may not be transferred or assigned without the prior written consent of the
Company. This Plan shall be binding upon any entity or person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company without regard to whether or not such entity or person actively
assumes the obligations hereunder and without regard to whether or not a Change in Control occurs. 

Section 7.    MITIGATION. 

Except as otherwise specifically provided in the Plan, an Eligible Employee will not be required to mitigate damages or the amount of any
payment provided under the Plan by seeking other employment or otherwise, nor will the amount of any payment provided for under the Plan be reduced by any compensation earned by an Eligible Employee as a result of employment by another employer or
any retirement benefits received by such Eligible Employee after the date of the Eligible Employee’s termination of employment with the Company. 

Section 8.    CLAWBACK; RECOVERY. 

All payments and severance benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the
Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer
Protection Act or other applicable law. In addition, the Plan Administrator may impose such other clawback, recovery or recoupment provisions as the Plan Administrator determines necessary or appropriate, including but not limited to a reacquisition
right in respect of previously acquired shares of common stock of the Company or other cash or property upon the occurrence of a termination of employment for Cause. No recovery of compensation under such a clawback policy will be an event giving
rise to a right to resign for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company. 

Section 9.    REEMPLOYMENT. 

In the event of an Eligible Employee’s reemployment by the Company during the period of time in respect of which severance benefits
pursuant to the Plan have been paid, the Company, in its sole and absolute discretion, may require such Eligible Employee to repay to the Company all or a portion of such severance benefits as a condition of reemployment. 

  
 8. 

 Section 10.    RIGHT TO INTERPRET
AND ADMINISTER PLAN; AMENDMENT OR TERMINATION. 

(a)    Interpretation and Administration. Prior to the effective date of a Change in Control, the Board shall
be the Plan Administrator and shall have the exclusive discretion and authority to establish rules, forms, and procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact,
interpretation, definition, computation or administration arising in connection with the operation of the Plan, including, but not limited to, the eligibility to participate in the Plan and amount of benefits paid under the Plan. The rules,
interpretations, computations and other actions of the Board shall be binding and conclusive on all persons. Upon and after the effective date of Change in Control, the Plan will be interpreted and administered in good faith by the Representative
who shall be the Plan Administrator during such period. All actions taken by the Representative in interpreting the terms of the Plan and administering the Plan upon and after the effective date of a Change in Control will be final and binding on
all Eligible Employees. Any references in this Plan to the “Board” or “Plan Administrator” with respect to periods following the effective date of a Change in Control shall mean the Representative. 

(b)    Amendment or Termination. The Plan Administrator reserves the right to amend or terminate this Plan
at any time, without advance notice to any Eligible Employee and without regard to the effect of the amendment or termination on any Eligible Employee or on any other individual, except as otherwise provided herein or in an individual Participation
Agreement. Any amendment or termination of the Plan will be in writing. Notwithstanding the foregoing, an Eligible Employee’s rights to receive payments and benefits pursuant to the Plan under an effective Participation Agreement may not be
adversely affected, without the Eligible Employee’s written consent, by an amendment or termination of the Plan. 

Section 11.    NO IMPLIED EMPLOYMENT CONTRACT. 

The Plan shall not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company or
(ii) to interfere with the right of the Company to discharge any employee or other person at any time, with or without cause, which right is hereby reserved. 

Section 12.    LEGAL CONSTRUCTION. 

This Plan is intended to be governed by and shall be construed in accordance with the Employee Retirement Income Security Act of 1974
(“ERISA”) and, to the extent not preempted by ERISA, the laws of the State of California. 

Section 13.    CLAIMS, INQUIRIES AND APPEALS. 

(a)    Applications for Benefits and Inquiries. Any application for benefits, inquiries about the Plan or
inquiries about present or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative). The Plan Administrator is: 

Bolt Biotherapeutics, Inc. 
 Board
of Directors 
 900 Chesapeake Drive 

Redwood City, CA 94063 

  
 9. 

 (b)    Denial of Claims. In the event that any application
for benefits is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant’s right to review the denial. Any electronic notice will
comply with the regulations of the U.S. Department of Labor. The notice of denial will be set forth in a manner designed to be understood by the applicant and will include the following: 

(1)    the specific reason or reasons for the denial; 

(2)    references to the specific Plan provisions upon which the denial is based; 

(3)    a description of any additional information or material that the Plan Administrator needs to complete the
review and an explanation of why such information or material is necessary; and 
 (4)    an explanation of the
Plan’s review procedures and the time limits applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described
in Section 13(d) below. 
 This notice of denial will be given to the applicant within ninety (90) days after the Plan
Administrator receives the application, unless special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for
processing is required, written notice of the extension will be furnished to the applicant before the end of the initial ninety (90) day period. 

This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan
Administrator is to render its decision on the application. 
 (c)    Request for a Review. Any person (or
that person’s authorized representative) for whom an application for benefits is denied, in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within sixty (60) days after the application
is denied. A request for a review shall be in writing and shall be addressed to: 
 Bolt Biotherapeutics, Inc. 

Board of Directors 
 900 Chesapeake
Drive 
 Redwood City, CA 94063 
 A request for
review must set forth all of the grounds on which it is based, all facts in support of the request and any other matters that the applicant feels are pertinent. The applicant (or his or her representative) shall have the opportunity to submit (or
the Plan Administrator may require the applicant to submit) written comments, documents, records, and other information relating to his or her claim. The applicant (or his or her representative) shall be provided, upon request and free of charge,
reasonable access to, and copies of, all documents, records and other information relevant to his or her claim. The review shall take into account all comments, documents, records and other information submitted by the applicant (or his or her
representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. 

(d)    Decision on Review. The Plan Administrator will act on each request for review within sixty
(60) days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension

  
 10. 

 
for review is required, written notice of the extension will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special
circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any
electronic notice will comply with the regulations of the U.S. Department of Labor. In the event that the Plan Administrator confirms the denial of the application for benefits in whole or in part, the notice will set forth, in a manner calculated
to be understood by the applicant, the following: 
 (1)    the specific reason or reasons for the denial; 

(2)    references to the specific Plan provisions upon which the denial is based; 

(3)    a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access
to, and copies of, all documents, records and other information relevant to his or her claim; and 
 (4)    a
statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA. 

(e)    Rules and Procedures. The Plan Administrator will establish rules and procedures, consistent with the
Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in connection with an appeal from the
denial of benefits to do so at the applicant’s own expense. 
 (f)    Exhaustion of Remedies. No
legal action for benefits under the Plan may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 13(a) above, (ii) has been notified by the Plan
Administrator that the application is denied, (iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section 13(c) above, and (iv) has been notified that the Plan
Administrator has denied the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to an Eligible Employee’s claim or appeal within the relevant time limits specified in this Section 13, the Eligible Employee
may bring legal action for benefits under the Plan pursuant to Section 502(a) of ERISA. 

Section 14.    BASIS OF PAYMENTS TO AND
FROM PLAN. 
 The Plan shall be unfunded, and all cash payments under the Plan shall be paid only from the
general assets of the Company. 
 Section 15.    OTHER PLAN INFORMATION. 

(a)    Employer and Plan Identification Numbers. The Employer Identification Number assigned to the Company
(which is the “Plan Sponsor” as that term is used in ERISA) by the Internal Revenue Service is 47-2804636. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the
Internal Revenue Service is 510. 
 (b)    Ending Date for Plan’s Fiscal Year. The date of the
end of the fiscal year for the purpose of maintaining the Plan’s records is December 31. 

  
 11. 

 (c)    Agent for the Service of Legal Process. The agent
for the service of legal process with respect to the Plan is: 
 Bolt Biotherapeutics, Inc. 

900 Chesapeake Drive 
 Redwood City,
CA 94063 
 In addition, service of legal process may be made upon the Plan Administrator. 

(d)    Plan Sponsor. The “Plan Sponsor” is: 

Bolt Biotherapeutics, Inc. 
 900
Chesapeake Drive 
 Redwood City, CA 94063 

(e)    Plan Administrator. The Plan Administrator is the Board prior to the effective date of a Change in
Control and the Representative upon and following such date. The Plan Administrator’s contact information is: 
 Bolt Biotherapeutics,
Inc. 
 Board of Directors or Representative 

900 Chesapeake Drive 
 Redwood City,
CA 94063 
 The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan. 

Section 16.    STATEMENT OF ERISA RIGHTS. 

Participants in this Plan (which is a welfare benefit plan sponsored by Bolt Biotherapeutics, Inc.) are entitled to certain rights and
protections under ERISA. If you are an Eligible Employee, you are considered a participant in the Plan and, under ERISA, you are entitled to: 

(a)    Receive Information About Your Plan and Benefits. 

(1)    Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as
worksites, all documents governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security
Administration; 
 (2)    Obtain, upon written request to the Plan Administrator, copies of documents governing
the operation of the Plan and copies of the latest annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Administrator may make a reasonable charge for the copies; and 

(3)    Receive a summary of the Plan’s annual financial report, if applicable. The Plan Administrator is
required by law to furnish each Eligible Employee with a copy of this summary annual report. 
 (b)    Prudent
Actions by Plan Fiduciaries. In addition to creating rights for Plan Eligible Employees, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan, called
“fiduciaries” of the Plan, have a duty to 

  
 12. 

 
do so prudently and in the interest of you and other Eligible Employees and beneficiaries. No one, including your employer, your union or any other person, may fire you or otherwise discriminate
against you in any way to prevent you from obtaining a Plan benefit or exercising your rights under ERISA. 

(c)    Enforce Your Rights. If your claim for a Plan benefit is denied or ignored, in whole or in part, you
have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 

Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents or the latest
annual report from the Plan, if applicable, and do not receive them within thirty (30) days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a
day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. 

If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court. 

If you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in
a Federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for
example, if it finds your claim is frivolous. 
 (d)    Assistance with Your Questions. If you have any
questions about the Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact
the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of
Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 

  
 13. 

 APPENDIX A 

BOLT BIOTHERAPEUTICS, INC. 

SEVERANCE AND CHANGE IN CONTROL PLAN 

PARTICIPATION AGREEMENT 

Name:                      

Section 1.    ELIGIBILITY. 

You have been designated as eligible to participate in the Bolt Biotherapeutics, Inc. Severance and Change in Control Plan (the
“Plan”), a copy of which is attached as Annex I to this Participation Agreement (the “Agreement”). Capitalized terms not explicitly defined in this Agreement but defined in the Plan shall have the same
definitions as in the Plan. 
 Section 2.    SEVERANCE BENEFITS. 

Subject to the terms of the Plan and Section 4 of this Agreement, if you are terminated in a Covered Termination, and meet all the other
eligibility requirements set forth in the Plan, including, without limitation, executing the required Release within the applicable time period set forth therein and provided that such Release becomes effective in accordance with its terms, you will
receive the severance benefits set forth in this Section 2. Notwithstanding the schedule for provision of severance benefits as set forth below, the provision of any severance benefits under this Section 2 is subject to any delay in
payment that may be required under Section 5 of the Plan. 
 (a)    Regular Termination. Upon a
Regular Termination, you shall be eligible to receive the following severance benefits during the [twelve (12) / nine (9) / six (6)] months following your employment termination (the “Severance Period”) . 

(1)    Cash Severance Benefits. You will be entitled to continue to receive the cash severance benefits set
forth below, which will be paid to you in equal payroll installments over the applicable Severance Period, provided however that any such payments otherwise scheduled to be made prior to the effective date of your Release will instead accrue and be
paid to you on the first payroll period following your Release effective date: 
 (i)    continued payment of
your Base Salary[; and 
 (ii)    an additional amount equal to a
pro-rata portion of the annual target cash bonus, if any, established for you by the Board (or an authorized committee or designee thereof) for the year in which your Regular Termination occurs. If at the time
of the Regular Termination you are eligible for the annual target cash bonus for the year in which the Regular Termination occurs, but the target percentage (or target dollar amount, if specified as such in the applicable bonus plan) for such bonus
has not yet been established for such year, the target percentage shall be the target percentage established for you for the preceding year (but adjusted, if necessary for your position for the year in which the Termination occurs). For the
avoidance of doubt, the amount of the pro-rata annual target bonus to which you are entitled under this Section 2(a)(1)(ii) will be calculated (1) assuming all articulated performance goals for such
bonus (including, but not limited to, corporate and individual performance, if applicable), for the year of the Regular Termination was achieved at 100% of the target performance levels; (2) with the
pro-rata portion of such amount determined by dividing the number of days you were employed by the Company for the year of the Regular Termination by the total number of

 
days in such calendar year; and (3) ignoring any reduction in your Base Salary that would give rise to your right to resign for Good Reason (such bonus to which you are entitled under this
Section 2(a)(1)(ii).][; and 
 (iii)    an additional amount equal to any performance bonus that you had
earned as of the date of your Regular Termination for the calendar year preceding the Regular Termination, but which has not yet been paid as of the date of your Regular Termination, if and to the extent applicable.] 

(2)    Payment of Continued Group Health Plan Benefits. 

(i)    If you timely elect continued group health plan continuation coverage under COBRA following your
termination date, the Company shall pay directly to the carrier the full amount of your COBRA premiums, or shall provide coverage under any self-funded plan, on behalf of you for your continued coverage under the Company’s group health plans,
including coverage for your eligible dependents, until the earliest of (i) the end of the Severance Period following the date of your termination, (ii) the expiration of your eligibility for the continuation coverage under COBRA, or
(iii) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment (such period from your termination date through the earliest of (i) through (iii), the “COBRA
Payment Period”). Upon the conclusion of such period of insurance premium payments made by the Company, or the provision of coverage under a self-funded group health plan, you will be responsible for the entire payment of premiums (or
payment for the cost of coverage) required under COBRA for the duration of your eligible COBRA coverage period. For purposes of this Section, (i) references to COBRA shall be deemed to refer also to analogous provisions of state law and
(ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are your sole
responsibility. You agree to promptly notify the Company as soon as you become eligible for health insurance coverage in connection with new employment or self-employment. 

(ii)    Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it
cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums
directly to the carrier on your behalf, the Company will instead pay you on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the COBRA premium for that month, subject to applicable tax
withholding (such amount, the “Special Severance Payment”), such Special Severance Payment to be made without regard to your election of COBRA coverage or payment of COBRA premiums and without regard to your continued
eligibility for COBRA coverage during the COBRA Payment Period. Such Special Severance Payment shall end upon expiration of the COBRA Payment Period. 

(b)    Change in Control Termination. Upon a Change in Control Termination, you shall be eligible to receive
the following severance benefits. For the avoidance of doubt, in no event shall you be entitled to benefits under both Section 2(a) and this Section 2(b). If you are eligible for severance benefits under both Section 2(a) and this
Section 2(b), you shall receive the benefits set forth in this Section 2(b) and such benefits shall be reduced by any benefits previously provided to you under Section 2(a). 

(1)    Cash Severance Benefit. You will receive the following cash severance benefit payable to you in a
single lump sum on the first payroll period following the later of (i) the effective date of your Release, or (ii) the effective date of the Change in Control,: 

 (i)    an amount equal to [eighteen (18) / twelve (12) / nine
(9)] of your Base Salary; plus 
 (ii)    [150% / 100% /75%] of your annual target cash bonus, if any,
established for you by the Board (or an authorized committee or designee thereof) for the year in which your Change in Control Termination occurs. If at the time of the Change in Control Termination you are eligible for the annual target cash bonus
for the year in which the Change in Control Termination occurs, but the target percentage (or target dollar amount, if specified as such in the applicable bonus plan) for such bonus has not yet been established for such year, the target percentage
shall be the target percentage established for you for the preceding year (but adjusted, if necessary for your position for the year in which the Change in Control Termination occurs). For the avoidance of doubt, the percentage of the annual target
bonus to which you are entitled under this Section 2(b)(1)(ii) will be calculated (1) assuming all articulated performance goals for such bonus (including, but not limited to, corporate and individual performance, if applicable), for the
year of the Change in Control Termination was achieved at 100% of the target levels; (2) as if you had provided services for the entire year for which the bonus relates; and (3) ignoring any reduction in your Base Salary that would give
rise to your right to resign for Good Reason.. 
 (2)    Accelerated Vesting of Stock Awards. 

(i)    Effective as of the later of the effective date of your Release or the effective date of the Change in
Control, to the extent not previously vested: (i) the vesting and exercisability of all outstanding stock options to purchase the Company’s common stock held by you on such date that were granted to you by the Company under the Equity Plan
shall be accelerated in full to the extent not previously fully vested and exercisable, (ii) any reacquisition or repurchase rights held by the Company in respect of common stock issued pursuant to any other stock award granted to you by the
Company under the Equity Plan shall lapse in full, and (iii) the vesting of any other unvested stock awards granted to you by the Company under the Equity Plan, and any issuance of shares triggered by the vesting of such stock awards or any
previously vested stock awards, shall be accelerated in full. For purposes of determining the number of shares that will vest pursuant to the foregoing provision with respect to any performance based vesting award that has multiple vesting levels
depending upon the level of performance, vesting acceleration shall occur with respect to the number of shares subject to the award as if the applicable performance criteria had been attained at a 100% of the target performance level. 

(ii)    In order to give effect to the intent of the foregoing provision, notwithstanding anything to the contrary
set forth in the Equity Plan or the applicable stock award agreement that provides that any then unvested portion of your award will immediately expire upon your termination of service, your stock awards shall remain outstanding following your
Change in Control Termination to give effect to such acceleration as necessary. 
 (iii)    Notwithstanding
anything to the contrary set forth herein, your stock awards shall remain subject to the terms of the Equity Plan or other applicable equity plan under which such awards were granted, including the stock award agreement governing your stock award,
that may apply upon a Change in Control and or/termination of your service and no provision of the Plan or this Agreement shall be construed as to limit the actions that may be taken, or to violate the terms, thereunder. 

(3)    Payment of Continued Group Health Plan Benefits. You will receive the payment for continued group
health plan benefits described in Section 2(a)(2) above, except that the COBRA Payment Period will be equal to the Severance Period applicable to a Change in Control Termination as set forth in Section 2(b)(1) above. 

 Section 3.    [CHANGE IN CONTROL
ACCELERATION. 
 Subject to the terms of Section 2(b)(2)(iii), if a Change in Control occurs while you are an
employee of the Company, 100% of the then-outstanding and unvested stock awards granted to you by the Company will immediately vest in full and, to the extent applicable, become immediately exercisable. If, however, an outstanding stock award is to
vest and/or the amount of the stock award to vest is to be determined based on the achievement of performance criteria, then the stock award will vest as to 100% of the amount of the stock award assuming the performance criteria had been achieved at
100% of the target performance levels for the relevant performance period(s).] 
 Section 4.    REQUIREMENTS
DURING SEVERANCE PERIOD. 
 Your eligibility for and receipt of any severance benefits to
which you may become entitled as described in Section 2 above is expressly contingent upon your timely execution of an effective Release and your compliance with the terms and conditions of the provisions of the Employee
Confidential Information and Invention Assignment Agreement between you and the Company dated [                    ] as may be amended from time to
time (the “CIIA”). Severance benefits under this Agreement shall immediately cease in the event of your violation of the provisions in this Section. 

Section 5.    ACKNOWLEDGEMENTS. 

As a condition to participation in the Plan, you hereby acknowledge each of the following: 

(a)    [If the IPO Date does not occur, the Plan will not become effective, and this Agreement will be void.] 

(b)    The severance benefits that may be provided to you under this Agreement are subject to all of the terms of
the Plan which is incorporated into and becomes part of this Agreement, including but not limited to the reductions under Section 3 of the Plan. 

(c)    Except as explicitly provided herein, contingent upon the IPO Date this Agreement and the Plan supersede and
replace any severance or change in control benefit previously provided to you by the Company, including any provisions to the contrary in your employment offer letter or agreement with the Company. This Agreement and the Plan do not supersede,
replace or otherwise alter the CIIA. 
 (d)    You may not sell, transfer, or otherwise assign or pledge your
right to benefits under this Agreement and the Plan to either your creditors or to your beneficiary, except to the extent permitted by the Plan Administrator if such action would not result in adverse tax consequences under Section 409A. 

(e)    Notwithstanding anything to the contrary in the Plan or this Agreement, your rights under this Agreement may
not be adversely affected by an amendment or termination of the Plan without your written consent. 
 To accept the terms of this Agreement and participate
in the Plan, please sign and date this Agreement in the space provided below and return it to [                    ] no later than
                    , 2021. 

							
	 Bolt Biotherapeutics, Inc.
	 		 	

							
				
	By:	 	 	 		 	
				
	Name:	 	 	 	                                    
                                         
       	 	                                    
                                
				
	Title:	 	 	 		 	
	    

    
     
	 		 	 
	[Eligible Employee]	 	Date

 ANNEX I 

BOLT BIOTHERAPEUTICS, INC. SEVERANCE AND CHANGE
IN CONTROL PLAN

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]